Biocon Limited

Price Chart

Risk-Adjusted Performance

Biocon Limited (BIOCON) Price Performance

Biocon Limited (BIOCON) trades on NSE in INR. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at INR369.05, down 3.12% from the previous close.

Over the past year, BIOCON has traded between a low of INR305.89 and a high of INR421.60. The stock has gained 6.1% over this period. It is currently 12.5% below its 52-week high.

Biocon Limited has a market capitalization of $635.10B, with a price-to-earnings ratio of 80.70.

About Biocon Limited

Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals, drug discovery, biotechnology pharmaceuticals, and medicinal sciences, etc.; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.